Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Huseyin Naci, M.H.S.

TitleVisiting Fellow in Population Medicine (EXT)
InstitutionHarvard Pilgrim Healthcare
DepartmentPopulation Medicine
AddressHarvard Vanguard Medical Associates
Dept. of Population Medicine 6th Flr
133 Brookline Ave
Boston MA 02215
vCardDownload vCard (login for email)

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Naci H, Dias S, Ades T. No evidence of industry sponsorship bias in statin trials. BMJ. 2014; 349:g6579.
    View in: PubMed
  2. Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Persistent medication affordability problems among disabled medicare beneficiaries after part d, 2006-2011. Med Care. 2014 Nov; 52(11):951-6.
    View in: PubMed
  3. Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ. 2014; 349:g5741.
    View in: PubMed
  4. Naci H, Ioannidis JP. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs? Annu Rev Pharmacol Toxicol. 2015 Jan 6; 55:169-89.
    View in: PubMed
  5. Naci H, van Valkenhoef G, Higgins JP, Fleurence R, Ades AE. Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. Circ Cardiovasc Qual Outcomes. 2014 Sep; 7(5):787-92.
    View in: PubMed
  6. Naci H, Soumerai SB, Ross-Degnan D, Zhang F, Briesacher BA, Gurwitz JH, Madden JM. Medication affordability gains following medicare part d are eroding among elderly with multiple chronic conditions. Health Aff (Millwood). 2014 Aug 1; 33(8):1435-43.
    View in: PubMed
  7. Naci H, Alexander GC. Regulators should better leverage effectiveness standards to enhance drug value. Pharmacotherapy. 2014 Oct; 34(10):1005-11.
    View in: PubMed
  8. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ. 2013; 347:f5577.
    View in: PubMed
  9. Naci H, O'Connor AB. Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. J Clin Epidemiol. 2013 Aug; 66(8):812-6.
    View in: PubMed
  10. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):390-9.
    View in: PubMed
  11. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013; 11:159.
    View in: PubMed
  12. Mossialos E, Naci H, Courtin E. Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence? Health Policy. 2013 Jul; 111(2):135-48.
    View in: PubMed
  13. Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 2013 Aug; 20(4):658-70.
    View in: PubMed
  14. Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013 Aug; 20(4):641-57.
    View in: PubMed
  15. Naci H, Brugts JJ, Fleurence R, Ades AE. Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. QJM. 2013 Apr; 106(4):299-306.
    View in: PubMed
  16. Winter HS, Mossialos E, Naci H, Chandra A, Salojee H, Yamashiro Y, Bhutta ZA, Uauy R, Corvalan C. The economics of health care delivery. J Pediatr Gastroenterol Nutr. 2012 Nov; 55(5):482-8.
    View in: PubMed
  17. Rahmioglu N, Naci H, Cylus J. Improving health care services in Northern Cyprus: a call for research and action. Eur J Public Health. 2012 Dec; 22(6):754-5.
    View in: PubMed
  18. Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K. Raising the bar for market authorisation of new drugs. BMJ. 2012; 345:e4261.
    View in: PubMed
  19. Chisholm D, Naci H, Hyder AA, Tran NT, Peden M. Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012; 344:e612.
    View in: PubMed
  20. Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. J Med Econ. 2012; 15(2):293-304.
    View in: PubMed
  21. Sorenson C, Naci H, Cylus J, Mossialos E. Evidence of comparative efficacy should have a formal role in European drug approvals. BMJ. 2011; 343:d4849.
    View in: PubMed
  22. Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood). 2010 Oct; 29(10):1826-33.
    View in: PubMed
  23. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010 Aug; 16(4):744-55.
    View in: PubMed
  24. Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ. 2010 Mar; 13(1):78-89.
    View in: PubMed
  25. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010; 28(5):363-79.
    View in: PubMed
  26. Naci H, Chisholm D, Baker TD. Distribution of road traffic deaths by road user group: a global comparison. Inj Prev. 2009 Feb; 15(1):55-9.
    View in: PubMed
  27. Naci H, Baker TD. Productivity losses from road traffic deaths in Turkey. Int J Inj Contr Saf Promot. 2008 Mar; 15(1):19-24.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Naci's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department